Savient Announces the Election of Robert G. Savage to its Board of Directors

 Savient Announces the Election of Robert G. Savage to its Board of Directors

PR Newswire

BRIDGEWATER, N.J., Dec. 5, 2012

BRIDGEWATER, N.J., Dec. 5, 2012 /PRNewswire/ --Savient Pharmaceuticals, Inc.
(NASDAQ: SVNT) today announced that Robert (Bob) G. Savage has been elected to
the Company's Board of Directors, effective December 5, 2012.

"Bob is a proven leader with an exceptional track record of success, and we
are fortunate to have a pharmaceutical executive with such a wealth of
experience join our Board of Directors," stated Stephen O. Jaeger, Chairman of
Savient's Board of Directors.

Mr. Savage is currently President and CEO of Strategic Imagery LLC, a
consulting company of which he is the principal. Previously, Mr. Savage was
Group Vice President and President of the Worldwide General Therapeutics &
Inflammation Business of Pharmacia Corporation from 2002 until its acquisition
by Pfizer, Inc. in 2003. Prior to that role, he held several senior positions
with Johnson & Johnson, including Worldwide Chairman of the Pharmaceuticals
Group, Company Group Chairman for the North American pharmaceuticals business,
President of Ortho-McNeil Pharmaceuticals and Vice President of Sales and
Marketing. Earlier in his career, he served in a variety of senior marketing,
operations, business development and strategic planning positions for
Hoffmann-La Roche, Inc. Mr. Savage currently serves as a director of EpiCept
Corporation, Nuovo Biologics and The Medicines Company. Mr. Savage received a
B.S. in Biology from Upsala College and an M.B.A. from Rutgers University.

"Given Bob's extensive experience in domestic and international marketing,
business development and operations, we are confident that he will immediately
prove to be an invaluable addition to the board and as an advisor to our
senior management team especially in light of the anticipated approval and
launch of KRYSTEXXA^® in the EU," said Lou Ferrari, President and Chief
Executive Officer of Savient. "His strategic vision and expertise in
orchestrating major product launches with renowned success will be
instrumental to Savient's ongoing commitment to providing KRYSTEXXA as a
treatment option to patients suffering from refractory chronic gout (RCG) in
the U.S. and around the world."

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused
on developing and commercializing KRYSTEXXA^® (pegloticase) for the treatment
of chronic gout in adult patients refractory to conventional therapy. Savient
has exclusively licensed worldwide rights to the technology related to
KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View
Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme
and MVP developed the PEGylation technology used in the manufacture of
KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing
and claiming the licensed technology and, in addition, Savient owns or co-owns
U.S. and foreign patents and patent applications, which collectively form a
broad portfolio of patents covering the composition, manufacture and methods
of use and administration of KRYSTEXXA. Savient also supplies Oxandrin^®
(oxandrolone tablets, USP) CIII in the U.S. For more information, please visit
the Company's website at


Savient Pharmaceuticals, Inc.                         Burns McClellan
John P. Hamill                                        Caitlyn Murphy
Senior Vice President and Chief Financial Officer                               (212) 213-0006
(732) 418-9300

SOURCE Savient Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.